News for Abeona Therapeutics Inc. (ABEO)

Abeona's ZEVASKYN approval and a $3.1 million price point are undervalued by the market. Find out why ABEO stock is a Buy.

Abeona Therapeutics (ABEO) has been recently highlighted by Oppenheimer with an "Outperform" rating. The new rating was assigned on June 2, 2025, as part of the

Oppenheimer has initiated coverage on Abeona Therapeutics (ABEO) with an "Outperform" rating and a price target of $19. The firm highlights the significant earl

Abeona Therapeutics (ABEO) has issued equity awards to newly hired non-executive staff members. These awards, aligned with Nasdaq Listing Rule 5635(c)(4), were

Abeona Therapeutics (ABEO) granted equity awards to five new non-executive employees. The awards consist of 11,500 restricted shares of common stock wit

CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in

Abeona Therapeutics (ABEO) to present at the Jefferies Global Healthcare Conference on June 4, 2025. The fireside chat will feature CEO Vish Seshadri an

**media[641412]**

U.S. stock futures were higher this morning, with the Dow futures gaining more than 500 points on Tuesday. Shares of PDD Holdings Inc. PDD fell sharply in toda...

On May 16, 2025, Mark Alvino, a Director at Abeona Therapeutics Inc (ABEO), sold 8,000 shares of the company, as reported in a SEC Filing. Following this transa

Weekly Market Recap Stocks had a winning week with the S&P 500 and Dow Jones Industrial Average turning positive for the year, up by 1.3% and 0.3% respecti

In a recent analysis, Stifel's Stephen Willey adjusted the price target for Abeona Therapeutics (ABEO), reducing it slightly from $21 to $20, while maintaining

Key Takeaways: Abeona Therapeutics Inc (ABEO) transitions into a commercial-stage company with FDA approval for ZEVASKYN. The stock shows potential for s

Alliance Global Partners has increased the target price for Abeona Therapeutics (ABEO) to $27.50 from a previous $25, maintaining a Buy rating on its shares. Th

Key Highlights: Abeona Therapeutics (ABEO) exceeds EPS expectations with a reported GAAP EPS of -$0.24. The company aims for significant growth with its

As of March 31, 2025, Abeona Therapeutics (ABEO) reported having $84.5 million in cash, cash equivalents, restricted cash, and short-term investments. This figu

Abeona Therapeutics (ABEO) has achieved a significant milestone with the recent approval of ZEVASKYN, marking a crucial development for patients suffering from

**media[626858]**

- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.